CN105749260A - 一种盐酸溶菌酶***片及其制备方法和应用 - Google Patents
一种盐酸溶菌酶***片及其制备方法和应用 Download PDFInfo
- Publication number
- CN105749260A CN105749260A CN201610308799.XA CN201610308799A CN105749260A CN 105749260 A CN105749260 A CN 105749260A CN 201610308799 A CN201610308799 A CN 201610308799A CN 105749260 A CN105749260 A CN 105749260A
- Authority
- CN
- China
- Prior art keywords
- lisozima
- temperature
- vaginal tablet
- lactose
- vaginal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000003 vaginal tablet Substances 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 229940073475 lysozyme hydrochloride Drugs 0.000 title abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 229940044977 vaginal tablet Drugs 0.000 claims description 92
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 68
- 230000001954 sterilising effect Effects 0.000 claims description 53
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 43
- 239000008101 lactose Substances 0.000 claims description 43
- 235000019359 magnesium stearate Nutrition 0.000 claims description 34
- 239000008176 lyophilized powder Substances 0.000 claims description 27
- 102000016943 Muramidase Human genes 0.000 claims description 26
- 108010014251 Muramidase Proteins 0.000 claims description 26
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 26
- 235000010335 lysozyme Nutrition 0.000 claims description 26
- 229960000274 lysozyme Drugs 0.000 claims description 25
- 239000004325 lysozyme Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- 206010046914 Vaginal infection Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 16
- 239000012467 final product Substances 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- 201000008100 Vaginitis Diseases 0.000 claims description 15
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 7
- 238000005374 membrane filtration Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 abstract description 21
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 14
- 239000000843 powder Substances 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 12
- 241000588724 Escherichia coli Species 0.000 abstract description 7
- 241000192125 Firmicutes Species 0.000 abstract description 7
- 230000002147 killing effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000007767 bonding agent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 44
- 210000001215 vagina Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 30
- 241000700159 Rattus Species 0.000 description 27
- 230000000844 anti-bacterial effect Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000033228 biological regulation Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000012086 standard solution Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000036512 infertility Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000193470 Clostridium sporogenes Species 0.000 description 5
- 208000003322 Coinfection Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 238000011047 acute toxicity test Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000007938 effervescent tablet Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000405070 Percophidae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000009642 citrate test Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 108010032809 mucopolysaccharidase Proteins 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940051921 muramidase Drugs 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610308799.XA CN105749260B (zh) | 2016-05-11 | 2016-05-11 | 一种盐酸溶菌酶***片及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610308799.XA CN105749260B (zh) | 2016-05-11 | 2016-05-11 | 一种盐酸溶菌酶***片及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105749260A true CN105749260A (zh) | 2016-07-13 |
CN105749260B CN105749260B (zh) | 2020-07-17 |
Family
ID=56323878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610308799.XA Active CN105749260B (zh) | 2016-05-11 | 2016-05-11 | 一种盐酸溶菌酶***片及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105749260B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619495A (zh) * | 2018-04-24 | 2018-10-09 | 金寨县鑫和新能源科技有限公司 | 一种辅助治疗盆腔积液的保健品的组合物 |
CN110846375A (zh) * | 2019-10-23 | 2020-02-28 | 崔璟 | 一种用于细菌电阻计数的培养基组合物、制备方法及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1663610A (zh) * | 2004-03-01 | 2005-09-07 | 孙明杰 | 溶菌酶新制剂 |
-
2016
- 2016-05-11 CN CN201610308799.XA patent/CN105749260B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1663610A (zh) * | 2004-03-01 | 2005-09-07 | 孙明杰 | 溶菌酶新制剂 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108619495A (zh) * | 2018-04-24 | 2018-10-09 | 金寨县鑫和新能源科技有限公司 | 一种辅助治疗盆腔积液的保健品的组合物 |
CN110846375A (zh) * | 2019-10-23 | 2020-02-28 | 崔璟 | 一种用于细菌电阻计数的培养基组合物、制备方法及其应用 |
CN110846375B (zh) * | 2019-10-23 | 2023-05-05 | 深圳艾尔生物科技有限公司 | 一种用于细菌电阻计数的培养基组合物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105749260B (zh) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8586549B2 (en) | Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity | |
US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
CN104306981B (zh) | 抗幽门螺杆菌活性抗菌肽胃黏膜纳米粒给药***制备方法 | |
CN102716168B (zh) | 一种含有利福昔明的用于预防和治疗奶牛干奶期***炎制剂及其制备方法 | |
CN102028705A (zh) | 一种含生物抑菌成分的妇科用品 | |
CN102727531A (zh) | 一种对***炎具有治疗和预防作用的活性乳酸菌胶囊 | |
CN108611295B (zh) | 一种缓解内毒素感染的脆弱拟杆菌及其应用 | |
CN103157095B (zh) | 芸豆植物凝集素在制备人用药物中的应用及其药物组合物 | |
CN105232526B (zh) | 含儿茶素的药物在制备抑菌药物中的用途 | |
CN109288889A (zh) | 一种抗菌妇科组合物、凝胶及其制备方法 | |
CN105749260A (zh) | 一种盐酸溶菌酶***片及其制备方法和应用 | |
CN109010529A (zh) | 一种用于女性***护理的中药抑菌凝胶剂 | |
CN102240260B (zh) | 一种治疗***干涩症的药物及其制备方法 | |
CN106581320A (zh) | 植物提取物的制备方法、含植物提取物的妇用制剂 | |
CN102614294B (zh) | 一种复方阿莫西林混悬注射剂及其制备方法 | |
EP1541162A1 (en) | Intravaginal washing agent | |
CN102743432B (zh) | 藿香油在制备治疗***炎的药物中的用途 | |
CN109078069A (zh) | ***黏膜抗菌凝胶剂及其制备方法 | |
CN108670951A (zh) | 一种兽用硫酸庆大霉素-盐酸林可霉素复方缓释注射液及其制备方法 | |
CN101618025B (zh) | 一种兽用盐酸多西环素冻干制剂及其制备方法 | |
CN100388949C (zh) | 一种用于防治牛子***的溶葡萄球菌酶冻干粉剂 | |
CN105749261A (zh) | 复方盐酸溶菌酶***片及其制备方法 | |
CN102641314A (zh) | 一种预防和/或治疗妇科疾病的药物组合物 | |
CN102552180B (zh) | 一种克林霉素磷酸酯组合物冻干粉针及其制备方法 | |
CN108478524A (zh) | 酮洛芬注射液及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210811 Address after: 250216 No. 3688, Longhu Road, Longshan office, Zhangqiu District, Jinan City, Shandong Province Patentee after: SHANDONG SIBANGDE PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG SBOND MEDICINE TRADE Co.,Ltd. Address before: 250216 Longshan office, Zhangqiu City, Jinan City, Shandong Province Patentee before: SHANDONG SIBANGDE PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a lysozyme hydrochloride vaginal tablet and a preparation method and application thereof Effective date of registration: 20210918 Granted publication date: 20200717 Pledgee: Ji'nan rural commercial bank Limited by Share Ltd. high tech branch Pledgor: SHANDONG SBOND MEDICINE TRADE Co.,Ltd. Registration number: Y2021370000109 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20200717 Pledgee: Ji'nan rural commercial bank Limited by Share Ltd. high tech branch Pledgor: SHANDONG SBOND MEDICINE TRADE Co.,Ltd. Registration number: Y2021370000109 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Lysozyme hydrochloride vaginal tablet and its preparation method and application Effective date of registration: 20221014 Granted publication date: 20200717 Pledgee: Ji'nan rural commercial bank Limited by Share Ltd. high tech branch Pledgor: SHANDONG SBOND MEDICINE TRADE Co.,Ltd. Registration number: Y2022980018234 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |